1,2:5,6-Di-O-isopropylidene-L-chiro-inositol (CAS 65556-81-2)

1,2:5,6-Di-O-isopropylidene-L-chiro-inositol, commonly known as DCI, has garnered significant attention in scientific research due to its potential roles in various biological processes, particularly in insulin signaling and cellular metabolism. As a derivative of inositol, DCI functions as a secondary messenger in cellular signaling pathways, notably influencing insulin sensitivity and glucose metabolism. Its mechanism of action primarily involves its ability to act as a mediator of the phosphatidylinositol 3-kinase (PI3K) signaling pathway, a key pathway involved in insulin-stimulated glucose uptake. DCI facilitates the activation of PI3K, leading to downstream signaling events that enhance the translocation of glucose transporter proteins to the cell membrane, thereby promoting glucose uptake into cells. Research on DCI has explored its potential implications in conditions associated with insulin resistance, such as type 2 diabetes and polycystic ovary syndrome (PCOS). Additionally, DCI supplementation has been investigated for its effects on metabolic parameters and reproductive health in both animal models and human clinical trials. Overall, DCI continues to be a subject of interest in scientific research, particularly in elucidating its molecular mechanisms and exploring its potential applications in metabolic disorders and related conditions.